The U.S. Food and Drug Administration (FDA) is encouraging scientists and drug developers to use an alpha-synuclein seed amplification assay (synSAA) to improve the development and efficiency of clinical trials seeking to delay or prevent the development of Parkinson’s and other neurodegenerative diseases that share toxic clumps of that protein…
Regeneron has joined the data syndication program for Koneksa‘s LEARNS study that’s assessing the potential of digital biomarkers for measuring the progression of Parkinson’s disease. The program enables Regeneron to gain immediate and continuous access to data and results as the trial progresses, which may accelerate the…
A newly developed biosensor that can rapidly detect and quantify levels of dopamine — a chemical messenger nerve cells use to communicate — may serve as a low-cost and efficient tool to diagnose and monitor people with Parkinson’s disease or other conditions marked by abnormal dopamine levels. Developed by…
Understanding and identifying epigenetic changes — those that affect gene activity without altering a gene’s DNA sequence — in blood samples from people with Parkinson’s disease and other neurological conditions may help assess the risk of dementia, two independent studies suggest. In one study, changes in DNA methylation, one…
A Phase 1 trial of ALX-001, an investigational therapy for neurodegenerative conditions, has dosed the first patient with Parkinson’s disease. The clinical trial (NCT06309147) is assessing the safety of Allyx Therapeutics‘ ALX-001 versus a placebo when given twice a day at either 50 mg or 100 mg for…
Having difficulty recognizing and describing emotions may be associated with cognitive issues and with mood disorders such as depression, apathy, and impulse control problems in people with Parkinson’s disease, a review study suggests. As a result, the condition, called alexithymia, or emotional blindness, may reduce patients’ health-related quality of…
The brain weakens unused neural connections in the striatum, a region involved in motor control and decision-making, through a nitric oxide-dependent mechanism that appears to be disrupted in Parkinson’s disease, a study in mice suggests. According to the researchers, these findings reveal some of the molecular mechanisms underlying the…
Having acute kidney injury increases the risk of developing dementia, including Parkinson’s disease with dementia, according to a study that suggests that people with kidney damage may benefit from close monitoring for early detection of cognitive decline. “Identifying acute kidney injury as a risk factor for dementia can lead…
GT-02287, an oral small molecule from Gain Therapeutics, was found to be safe and well tolerated in healthy volunteers. It was also able to reach its target area, the brain, showing it has potential as a treatment for Parkinson’s disease linked to the GBA gene. The company plans…
The U.S. Food and Drug Administration (FDA) has again cleared Rebrain’s OptimMRI software, this time including a new machine learning model to assist in targeting specific brain regions for lesioning techniques such as MR-guided focused ultrasound and radiosurgery. Lesioning techniques involve the destruction of small areas of abnormal brain…
Get regular updates to your inbox.
